SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumors.

Locally Advanced ◽

Metastatic Breast ◽

Pi3 Kinase ◽

Pi3k Inhibitor ◽

Phase Iii ◽

Er Positive ◽

SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumours

Annals of Oncology ◽

10.1093/annonc/mdw365.92 ◽

2016 ◽

Vol 27 ◽

pp. vi99 ◽

Cited By ~ 2

Author(s):

J. Baselga ◽

J. Cortes Castan ◽

M. De Laurentiis ◽

V. Dieras ◽

N. Harbeck ◽

...

Keyword(s):

Breast Cancer ◽

Oestrogen Receptor ◽

Locally Advanced ◽

Metastatic Breast ◽

Pi3 Kinase ◽

Pi3k Inhibitor ◽

Phase Iii ◽

Er Positive ◽

Abstract OT2-01-01: SANDPIPER: Phase III study of the PI3-kinase inhibitor taselisib (GDC-0032) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients withPIK3CA-mutant tumors

10.1158/1538-7445.sabcs16-ot2-01-01 ◽

2017 ◽

Author(s):

J Baselga ◽

J Cortés ◽

M De Laurentiis ◽

S Dent ◽

V Diéras ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Kinase Inhibitor ◽

Locally Advanced ◽

Metastatic Breast ◽

Pi3 Kinase ◽

Phase Iii ◽

Estrogen Receptor Positive ◽

Faculty Opinions recommendation of Phase III study of taselisib (GDC-0032) + fulvestrant (FULV)v FULV in patients (pts) with estrogen receptor (ER)-positive,PIK3CA -mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.733514289.793559077 ◽

2019 ◽

Author(s):

Ahmad Awada

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase Iii ◽

Primary Analysis ◽

Er Positive ◽

Abstract OT1-03-14: SANDPIPER: Phase III study of the PI3-kinase inhibitor taselisib (GDC-0032) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients withPIK3CA-mutant tumors

10.1158/1538-7445.sabcs15-ot1-03-14 ◽

2016 ◽

Author(s):

J Baselga ◽

J Cortés ◽

M De Laurentiis ◽

V Diéras ◽

N Harbeck ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Kinase Inhibitor ◽

Locally Advanced ◽

Metastatic Breast ◽

Pi3 Kinase ◽

Phase Iii ◽

Estrogen Receptor Positive ◽

Abstract OT2-3-08: Phase III randomized study of the oral pan-PI3K inhibitor BKM120 with fulvestrant in postmenopausal women with HR+/HER2– locally advanced or metastatic breast cancer, treated with aromatase inhibitor, and progressed on or after mTOR inhibitor-based treatment – BELLE-3

10.1158/0008-5472.sabcs12-ot2-3-08 ◽

2012 ◽

Cited By ~ 3

Author(s):

A Di Leo ◽

C Germa ◽

D Weber ◽

E Di Tomaso ◽

B Dharan ◽

...

Keyword(s):

Breast Cancer ◽

Aromatase Inhibitor ◽

Postmenopausal Women ◽

Mtor Inhibitor ◽

Randomized Study ◽

Locally Advanced ◽

Metastatic Breast ◽

Pi3k Inhibitor ◽

Phase Iii

Abstract OT3-2-09: FALCON: A randomised, double-blind, multicentre, phase III study comparing fulvestrant 500 mg with anastrozole 1 mg for postmenopausal women with hormone receptor-positive locally advanced or metastatic breast cancer who have not previously been treated with any hormonal therapy

10.1158/0008-5472.sabcs13-ot3-2-09 ◽

2013 ◽

Author(s):

MJ Ellis ◽

M Prahladan ◽

NL Green ◽

E Mari ◽

JFR Robertson

Keyword(s):

Breast Cancer ◽

Hormonal Therapy ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase Iii ◽

Double Blind ◽

Multicentre Phase ◽

Hormone Receptor Positive ◽

355TiP Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) + fulvestrant (F) in patients (pts) with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2– LA/MBC)

Annals of Oncology ◽

10.1016/j.annonc.2020.08.457 ◽

2020 ◽

Vol 31 ◽

pp. S391-S392

Author(s):

N. Turner ◽

K. Jhaveri ◽

K. Kalinsky ◽

S. Loibl ◽

S. Loi ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase Iii ◽

Hormone Receptor Positive ◽

Abstract OT2-3-09: Phase III randomized study of the oral pan-PI3K inhibitor BKM120 with fulvestrant in postmenopausal women with HR+/HER2– locally advanced or metastatic breast cancer resistant to aromatase inhibitor – BELLE-2

10.1158/0008-5472.sabcs12-ot2-3-09 ◽

2012 ◽

Cited By ~ 3

Author(s):

J Baselga ◽

M Campone ◽

J Cortes ◽

H Iwata ◽

M de Laurentiis ◽

...

Keyword(s):

Breast Cancer ◽

Aromatase Inhibitor ◽

Postmenopausal Women ◽

Randomized Study ◽

Locally Advanced ◽

Metastatic Breast ◽

Pi3k Inhibitor ◽

Phase Iii

Abstract S4-07: BELLE-3: A phase III study of buparlisib + fulvestrant in postmenopausal women with HR+, HER2–, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment

10.1158/1538-7445.sabcs16-s4-07 ◽

2017 ◽

Cited By ~ 19

Author(s):

A Di Leo ◽

K Seok Lee ◽

E Ciruelos ◽

P Lønning ◽

W Janni ◽

...

Keyword(s):

Breast Cancer ◽

Aromatase Inhibitor ◽

Postmenopausal Women ◽

Mtor Inhibitor ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase Iii ◽

Abstract OT-36-01: Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) + fulvestrant (F) in patients withPIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2- LA/MBC)

10.1158/1538-7445.sabcs20-ot-36-01 ◽

2021 ◽

Author(s):

Nicolas Turner ◽

Komal Jhaveri ◽

Kevin Kalinsky ◽

Sibylle Loibl ◽

Sherene Loi ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase Iii ◽

Hormone Receptor Positive ◽